ALIM Stock Analysis
AL
Uncovered
Alimera Sciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 145 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The firm focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The firm commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.